================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 2 TO
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the year ended October 31, 2002
Or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 Or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Commission file number: 0-45138
SYNOPSYS, INC.
(Exact name of registrant as specified in its charter)
Delaware 56-1546236
(State or other jurisdiction (I.R.S. Employer incorporation
of or organization) Identification No.)
700 East Middlefield Road, Mountain View, California 94043
(Address of Principal Executive Offices)
(650) 584-5000
Registrant's telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act: None
Securites registered pursuant to Section 12(g) of the Act:
Common Stock, $0.01 par value
---------------------------
Preferred Share Purchase Rights
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 (the "Act") during the preceding 12 months (or for such shorter period that
the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Act).
[ ] Yes [X] No
State the aggregate market value of the voting and non-voting common equity
held by non-affiliates computed by reference to the price at which the common
equity was last sold, or the average bid and asked price of such common equity,
as of the last business day of the registrant's most recently completed second
fiscal quarter: $1,699,717,300.
The aggregate market value of voting stock held by non-affiliates of the
registrant as of February 6, 2003, was approximately $2,792,883,845.
On February 21, 2003, approximately 74,393,514 shares of the registrant's
Common Stock, $0.01 par value, were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
None.
================================================================================
II-2
EXPLANATORY NOTE
This Amendment No. 2 to the Registrant's Annual Report on Form 10-K for
the fiscal year ended October 31, 2002 is being filed in order to submit the
information required to be included in Part III thereof within the period
required by General Instruction G(3) to Form 10-K. The Registrant will also
include this information in its proxy statement for its 2003 Annual Meeting of
Stockholders.
PART III
Item 10. Directors and Executive Officers of the Registrant
Set forth below is information regarding the directors, including
information furnished by them as to principal occupations, certain other
directorships held by them, any arrangements pursuant to which they were
selected as directors and their ages as of January 31, 2003.
Year First
Elected
Name Age Director
------------------------------------------------- ------ --------------
Aart J. de Geus................................... 48 1986
Andy D. Bryant.................................... 52 1999
Chi-Foon Chan..................................... 53 1998
Bruce R. Chizen................................... 47 2001
Deborah A. Coleman................................ 50 1995
A. Richard Newton................................. 51 1987; 1995
Sasson Somekh..................................... 56 1999
Roy Vallee........................................ 50 2003
Steven C. Walske.................................. 50 1991
Background of Directors
Dr. Aart J. de Geus co-founded Synopsys and currently serves as Chief
Executive Officer and Chairman of the Board of Directors. Since the inception of
Synopsys in December 1986, he has held a variety of positions, including Senior
Vice President of Engineering and Senior Vice President of Marketing. From 1986
to 1992, Dr. de Geus served as Chairman of the Board. He served as President
from 1992 to 1998. Dr. de Geus has served as Chief Executive Officer since
January 1994 and has held the additional title of Chairman of the Board since
February 1998. He has served as a Director since 1986. From 1982 to 1986 Dr. de
Geus was employed by General Electric Corporation, where he was the Manager of
the Advanced Computer-Aided Engineering Group. Dr. de Geus holds an M.S.E.E.
from the Swiss Federal Institute of Technology in Lausanne, Switzerland and a
Ph.D. in electrical engineering from Southern Methodist University.
Andy D. Bryant has been a Director of Synopsys since January 1999 and
currently serves as Executive Vice President and Chief Financial and Enterprise
Services Officer of Intel Corporation, with responsibility for financial
operations, human resources, information technology and e-business functions and
activities worldwide. Mr. Bryant joined Intel in 1981 as Controller for the
Commercial Memory Systems Operation and in 1983 became Systems Group Controller.
In 1987 he was promoted to Director of Finance for the corporation and was
appointed Vice President and Director of Finance of the Intel Products Group in
1990. Mr. Bryant became CFO in February of 1994 and was promoted to Senior Vice
President in January 1999. Mr. Bryant expanded his role to Chief Financial and
Enterprise Services Officer in December 1999. He was promoted to Executive Vice
President in January 2001. Prior to joining Intel, he held positions in finance
at Ford Motor Company and Chrysler Corporation. Mr. Bryant holds a B.A. in
economics from the University of Missouri and an M.B.A. in finance from the
University of Kansas.
II-2
Dr. Chi-Foon Chan joined Synopsys as Vice President of
Application Engineering & Services in May 1990. Since April 1997 he has served
as Chief Operating Officer and since February 1998 he has held the additional
title of President. Dr. Chan also became a Director of Synopsys in February
1998. From September 1996 to February 1998 he served as Executive Vice
President, Office of the President. From February 1994 until April 1997 he
served as Senior Vice President, Design Tools Group and from October 1996 until
April 1997 as Acting Senior Vice President, Design Re-Use Group. Additionally,
he has held the titles of Vice President, Engineering and General Manager,
DesignWare Operations and Senior Vice President, Worldwide Field Organization.
From March 1987 to May 1990, Dr. Chan was employed by NEC Electronics, where his
last position was General Manager, Microprocessor Division. From 1977 to 1987,
Dr. Chan held a number of senior engineering positions at Intel Corporation. Dr.
Chan holds an M.S. and Ph.D. in computer engineering from Case Western Reserve
University.
Bruce R. Chizen has been a Director of Synopsys since April 2001. Mr.
Chizen has served as President of Adobe Systems Incorporated, a provider of
graphic design, publishing, and imaging software for Web and print production,
since April 2000 and as Chief Executive Officer since December 2000. He joined
Adobe Systems in August 1994 as Vice President and General Manager, Consumer
Products Division and in December 1997 became Senior Vice President and General
Manager, Graphics Products Division. In August 1998 Mr. Chizen was promoted to
Executive Vice President, Products and Marketing. From November 1992 to February
1994 he was Vice President and General Manager, Claris Clear Choice for Claris
Corp., a wholly-owned subsidiary of Apple Computer. He is a Director of Adobe
Systems Incorporated.
Deborah A. Coleman has been a Director of Synopsys since November 1995.
Ms. Coleman is co-founder and currently General Partner of SmartForest Ventures
in Portland, Oregon. Ms. Coleman was Chairman of the Board of Merix Corporation,
a manufacturer of printed circuit boards, from May 1994, when it was spun off
from Tektronix, Inc., until September 2001. She also served as Chief Executive
Officer of Merix from May 1994 to September 1999 and as President from March
1997 to September 1999. Ms. Coleman joined Merix from Tektronix, a diversified
electronics corporation, where she served as Vice President of Materials
Operations, responsible for worldwide procurement, distribution, component
engineering and component manufacturing operations. Prior to joining Tektronix
in November 1992, Ms. Coleman was with Apple Computer, Inc. for eleven years,
where she held several executive positions, including Chief Financial Officer,
Chief Information Officer and Vice President of Operations. She is a Director of
Applied Materials, Inc., a manufacturer of semiconductor fabrication equipment,
Chairman of the Board of Teseda Corporation, a semiconductor test equipment
company, and a director of Finatus, Inc., a web-based compliance service
provider.
Dr. A. Richard Newton has been a Director of Synopsys since January
1995. Previously, Dr. Newton was a Director of Synopsys from January 1987 to
June 1991. Dr. Newton has been a Professor of Electrical Engineering and
Computer Sciences at the University of California at Berkeley since 1979 and is
currently Dean of the College of Engineering. From July 1999 to June 2000, Dr.
Newton was Chair of the Electrical Engineering and Computer Sciences Department.
Since 1988 Dr. Newton has acted as a Venture Partner with Mayfield Fund, a
venture capital partnership, and has contributed to the evaluation and
development of over two dozen new companies. From November 1994 to July 1995 he
was acting President and Chief Executive Officer of Silicon Light Machines, a
private company which has developed display systems based on the application of
micromachined silicon light-valves.
Dr. Sasson Somekh has been a Director of Synopsys since January 1999.
He is Executive Vice President of Applied Materials, Inc., a manufacturer of
semiconductor fabrication equipment. From December 1993 to November 2000, Dr.
Somekh served as Senior Vice President. Dr. Somekh served as Group Vice
President from 1990 to 1993. Prior to that, he was a divisional Vice President.
Dr. Somekh joined Applied Materials in 1980 as a Project Manager.
Roy Vallee has been a Director of Synopsys since February 2003. Mr.
Vallee is Chief Executive Officer and Chairman of the Board of Avnet, Inc.,
a global semiconductor products and electronics distributor, positions he has
held since June 1998. Previously, he was Vice Chairman of the Board since
November 1992, and also President and Chief Operating Officer since March
1992. Mr. Vallee currently serves on the board of directors of Teradyne,
Inc., an automated testing company for the electronics, communications and
software industries. He is also a member of the executive committee of
the Global Technology Distribution Council.
II-3
Steven C. Walske has been a Director of Synopsys since December 1991.
Mr. Walske has been Chief Business Strategist of Parametric Technology
Corporation, a supplier of software products for mechanical computer aided
engineering since June 2000. Previously, Mr. Walske served as Chairman, Chief
Executive Officer and a Director from August 1994 until June 2000 and as
President and Chief Executive Officer of that company from December 1986 to
August 1994.
There are no family relationships among any executive officers,
directors or persons chosen or nominated to become executive officers or
directors of Synopsys.
Directors' Compensation
Each member of the Board receives a retainer of $25,000 per year for
attendance at Board meetings. In addition, each member of the Audit Committee
receives $2,000 per Audit Committee meeting attended, other than the
Chairperson, who receives $4,000 per Audit Committee meeting attended.
In addition, non-employee members of the board of directors receive
automatic option grants under the 1994 Non-Employee Directors Stock Option Plan,
which in this document we refer to as the "Directors Plan." As of the date of
this Annual Report, all seven non-employee members of the Synopsys board of
directors were eligible to participate in the Directors Plan. Under the
Directors Plan, new directors receive an option for 20,000 shares, vesting in
equal installments over four years. In addition, each continuing director who
is elected at an annual meeting of stockholders receives an option for 10,000
shares and an additional option for 5,000 shares for each Board committee
membership. The annual option grants vest in full on the date immediately prior
to the date of the annual meeting following their grant. In the case of
directors appointed to the board between annual meetings, the annual and any
committee grants are prorated based upon the amount of time since the last
annual meeting.
During fiscal 2002, directors Andy D. Bryant, Bruce R. Chizen, Deborah
A. Coleman, A. Richard Newton, Sasson Somekh and Steven C. Walske each received
automatic grants of options to purchase 10,000 Synopsys common shares at an
exercise price of $49.83 per share for Synopsys board of directors service
during the year. In addition, during fiscal 2002, each of such directors
received options to purchase 10,000 Synopsys common shares for service on
Synopsys board of directors committees at an exercise price of $49.83. Mr.
Vallee, who was added to the Board in February 2003, received an option for
20,000 shares at an exercise price of $40.92 for his initial service, a pro
rated annual grant of 3,333 shares at an exercise price of $40.92 per
share and a pro rated committee grant of 3,333 shares at an exercise price of
$40.46 per share.
During fiscal 2002, Dr. Newton provided consulting services to
Synopsys, for which he was paid $180,000. Under Synopsys' agreement with Dr.
Newton, at Synopsys' request, Dr. Newton provides advice concerning long-term
technology strategy and industry development issues, as well as assistance in
identifying opportunities for partnerships with academia.
II-4
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires Synopsys' directors,
officers and greater than ten percent beneficial owners of its shares to file
reports of ownership and changes in ownership with the SEC. Directors, officers
and greater than ten percent stockholders are required by SEC regulations to
furnish Synopsys with copies of all Section 16(a) forms they file.
Based solely upon its review of the copies of the Forms 3, 4 and 5
received by Synopsys and/or written representations from certain reporting
persons, Synopsys believes that each of its directors, officers, and greater
than ten percent beneficial owners of its shares during the fiscal year ended
October 31, 2002 has complied with all filing requirements applicable to such
persons during such fiscal year.
Executive Officers
Information regarding executive officers who are not directors is
included in Part I of the Annual Report.
Item 11. Executive Compensation
Executive Compensation And Other Matters
The following table sets forth the compensation earned by (1) Synopsys'
Chief Executive Officer and (2) each of the other four most highly compensated
executive officers whose compensation for fiscal 2002 exceeded $100,000, which
in this document we collectively refer to as the "named executive officers," for
services rendered in all capacities to Synopsys during the last three fiscal
years.
Summary Compensation Table
Long-Term
Compensation:
Securities
Awards All Other
Annual Compensation ($) Underlying Compensation
Name and Position Year Salary Bonus Options (#) ($) (1)
------------------ ---- ------ ----- ------------ ------------
Aart J. de Geus........................... 2002 446,154 575,000 106,500 1,500
Chief Executive Officer and 2001 400,000 575,000 85,500 1,830
Chairman of the Board 2000 430,769 600,000 731,000 1,855
Chi-Foon Chan............................. 2002 400,000 575,000 91,700 5,138
President and Chief Operating 2001 400,000 575,000 71,000 2,588
Officer 2000 430,769 600,000 623,000 2,493
Vicki L. Andrews.......................... 2002 300,000 448,385(2) 72,900 13,884
Senior Vice President 2001 289,423 611,396(3) 60,500 9,544
World Wide Sales 2000 287,500 568,256(4) 179,000 9,826
Robert B. Henske.......................... 2002(5) 375,000 350,000 73,300 1,500
Senior Vice President and 2001 364,423 350,000 60,500 1,825
Chief Financial Officer 2000(6) 175,000 232,000 340,000 160
Steven K. Shevick(7)...................... 2002 250,000 220,000 25,300 1,500
Senior Vice President and Chief 2001 241,538 175,000 17,500 1,871
Financial Officer
2000 236,154 160,984 100,000 1,833
--------------------------------------------------------------------------------
(1) Amounts in this column reflect premiums paid for group term life insurance,
Synopsys 401(k) contributions and, in the case of Ms. Andrews only, car
allowances. Dr. Chan's 2002 amounts include special travel allowance.
(2) Ms. Andrews' 2002 bonus consists of commissions of $102,125 and variable
bonus of $346,260.
(3) Ms. Andrews' 2001 bonus consists of commissions of $150,000, a variable
bonus of $296,260, a relocation bonus of $160,000 and a special bonus of
$5,136.
(4) Ms. Andrews' 2000 bonus consists of commissions of $318,096 and a variable
bonus of $250,160.
(5) Mr. Henske resigned from his position effective
January 3, 2003.
(6) Mr. Henske commenced employment with Synopsys on May
10, 2000.
(7) Mr. Shevick was appointed Chief Financial Officer of Synopsys on January 2,
2003. Prior to that, he served as Vice President, Investor Relations and
Legal and General Counsel.
II-5
Stock Option Grants, Option Exercises and Year-End Values
Information regarding stock option grants, option exercises and
year-end values for the named executive officers during fiscal 2002 is included
in Item 7 of this Annual Report.
Employment Contracts, Termination of Employment Arrangements and Change of
Control Agreements
Under Synopsys' 1992 Stock Option Plan ("1992 Plan"), in the event of
certain changes in the ownership or control of Synopsys involving a "Corporate
Transaction," which includes an acquisition of Synopsys by merger or asset
sales, all outstanding options under the 1992 Plan will automatically become
exercisable, unless the option is assumed by the successor corporation, or
parent thereof, or replaced by a comparable option to purchase shares of the
capital stock of the successor corporation, or parent thereof.
In addition, in the event of a successful hostile tender offer for more
than 50% of the outstanding Synopsys common shares or a change in the majority
of the Synopsys board of directors as a result of one or more contested
elections for membership on the Synopsys board of directors, the administrator
of the 1992 Plan has the authority to accelerate vesting of outstanding options
or shares purchased under the 1992 Plan.
The Directors Plan provides that in the event of a change of control or
corporate transaction, as such terms are defined in the Directors Plan, all
Directors Plan options held by such director shall become fully vested and
exercisable as of the date of such change of control or corporate transaction.
Synopsys has entered into Employment Agreements, effective October 1,
1997, with its Chief Executive Officer and its President. Each Employment
Agreement provides that if the executive is terminated involuntarily other than
for cause within 24 months of a change of control, (a) the executive will be
paid an amount equal to two times the sum of the executive's annual base pay
plus target cash incentive, plus the cash value of the executive's health
benefits for the next 18 months, and (b) all stock options held by the executive
will immediately vest in full. If the executive is terminated involuntarily
other than for cause in any other situation, the executive will receive a cash
payment equal to the sum of the executive's annual base pay for one year plus
the target cash incentive for such year, plus the cash value of the executive's
health benefits for 12 months. The terms "involuntary termination," "cause" and
"change of control" are defined in the Employment Agreements, each of which is
filed with the SEC.
II-6
Item 12. Security Ownership of Certain Beneficial Owners and Management
The following table sets forth certain information with respect to the
beneficial ownership of Synopsys common shares by (1) each person known by
Synopsys to own beneficially more than five percent of the outstanding Synopsys
common shares on that date, and, (2) as of February 6, 2003 (A) each Synopsys
director, (B) each of the named executive officers and (C) all Synopsys
directors and current executive officers as a group.
Shares of Common Stock
Beneficially Owned
Percentage
Name of Beneficial Owner(1) Number Ownership
---------------------------- ----------- ----------
J. & W. Seligman & Co. Incorporated.......... 7,776,496(2) 10.28%
100 Park Avenue, 8th Floor
New York, NY 10017
Franklin Resources, Inc...................... 5,291,927(3) 7.0%
One Frankling Parkway
San Mateo, CA 94403-1906
Blum Capital Partners, L.P.................. 4,906,200(4) 6.61%
909 Montgomery Street, Suite 400
San Francisco, CA 94133-4625
FMR Corp..................................... 4,785,520(5) 6.33%
82 Devonshire Street, Boston,
Massachusetts 02109
Harris Associates L.P........................ 3,805,900(6) 5.03%
Two North LaSalle Street,
Suite 500
Chicago, IL 60602-3790
Vicki L. Andrews............................. 128,653(7) *
Andy D. Bryant............................... 93,749(8) *
Chi-Foon Chan................................ 939,867(9) 1.25%
Bruce R. Chizen.............................. 59,166(10) *
Deborah A. Coleman........................... 60,000(11) *
Aart J. de Geus.............................. 1,708,165(12) 2.26%
Robert B. Henske............................. 0 *
A. Richard Newton............................ 95,916(13) *
Steven K. Shevick............................ 128,663(14) *
Sasson Somekh................................ 113,333(15) *
Roy Vallee................................... 0 *
Steven C. Walske............................. 116,016(16) *
All directors and current executive.......... 3,443,528(17) 4.45%
officers as a group (11 persons)
----------------------------
* Less than 1%
(1) The persons named in the table above have sole voting and investment power
with respect to all Synopsys common shares shown as beneficially owned by
them, subject to community property laws where applicable and the
information contained in the footnotes of this table.
(2) Share ownership for J. & W. Seligman & Co. Incorporated was obtained from
Amendment No. 11 to the Schedule 13G filed with the Securities and Exchange
Commission on February 11, 2003.
(3) Share ownership for Franklin Resources was obtained from Amendment No. 2 to
the Schedule 13D filed with the Securities and Exchange Commission on
February 12, 2003. Includes 2,127,450 shares as to which Franklin Advisers,
Inc. has sole voting power, 1,921,522 shares as to which Templeton Global
Advisers Limited has sole voting power, 448,785 shares as to which
Fiduciary Trust Company International has sole voting power, 411,068 shares
as to which Franklin Templeton Investment Management Limited has sole
voting power , 232,110 shares as to which Templeton Investment Counsel, LLC
has sole voting power, 147,817 shares as to which Franklin Templeton
Investments Corp. has sole voting power and 3,175 shares as to which
Templeton/Franklin Investment Services, Inc. has sole voting power.
II-7
(4) Share ownership for Blum Capital Partners, L.P. was obtained from Schedule
13F-R filed with the Securities and Exchange Commission on February 14,
2003.
(5) Share ownership for FMR Corp. was obtained from Amendment No. 2 to the
Schedule 13D filed with the Securities and Exchange Commission on February
14, 2003.
(6) Share ownership for Harris Associates L.P. was obtained from Schedule 13G
filed with the Securities and Exchange Commission on February 14, 2003.
Includes 1,620,900 shares over which Harris Associates L.P. has sole voting
power and 2,185,000 shares over which Harris Associates L.P. has shared
voting power.
(7) Includes options to purchase 127,975 Synopsys common shares exercisable by
Ms. Andrews within 60 days of February 6, 2003.
(8) Consists of options to purchase 93,749 Synopsys common shares exercisable
by Mr. Bryant within 60 days of February 6, 2003.
(9) Includes options to purchase 907,633 Synopsys common shares exercisable by
Dr. Chan within 60 days of February 6, 2003.
(10) Consists of options to purchase 59,166 Synopsys common shares exercisable
by Mr. Chizen within 60 days February 6, 2003.
(11) Consists of options to purchase 60,000 Synopsys common shares exercisable
by Ms. Coleman within 60 days of February 6, 2003.
(12) Includes options to purchase 1,396,131 Synopsys common shares exercisable
by Dr. de Geus within 60 days of February 6, 2003.
(13) Consists of options to purchase 95,916 Synopsys common shares exercisable
by Dr. Newton within 60 days of February 6, 2003.
(14) Includes options to purchase 126,352 Synopsys common shares exercisable by
Mr. Shevick within 60 days of February 6, 2003.
(15) Includes options to purchase 100,833 Synopsys common shares exercisable by
Dr. Somekh within 60 days of February 6, 2003.
(16) Includes options to purchase 115,916 Synopsys common shares exercisable by
Mr. Walske within 60 days of February 6, 2003.
(17) Includes options to purchase 3,083,671 Synopsys common shares exercisable
by directors and current executive officers within 60 days of February 6,
2003.
Item 13. Certain Relationships and Related Transactions
See Item 10, "Directors and Executive Officers of the Registrant-Directors'
Compensation."
II-8
SIGNATURES
Pursuant to the requirements of section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this amendment to be signed
on its behalf by the undersigned, thereunto duly authorized, in Mountain View,
State of California, on this 28th day of February, 2003.
SYNOPSYS, INC.
By: /s/ Aart J. de Geus
Aart J. de Geus
Chief Executive Officer and
Chairman of the Board of Directors
(Principal Executive Officer)
By: /s/ Steven K. Shevick
Steven K. Shevick
Senior Vice President, Finance
and Chief Financial Officer
(Principal Financial Officer)
By: /s/ Richard T. Rowley
Richard T. Rowley
Vice President, Corporate Controller
(Principal Accounting Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934,
this amendment has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated:
Signature Title Date
/s/ AART J. DE GEUS Chief Executive Officer February 28, 2003
Aart J. de Geus (Principal Executive Officer)
and Chairman of the Board of Directors
/s/ CHI-FOON CHAN* President, Chief Operating Officer February 28, 2003
Chi-Foon Chan and Director
/s/ BRUCE R. CHIZEN* Director February 28, 2003
Bruce R. Chizen
/s/ ANDY D. BRYANT* Director February 28, 2003
Andy D. Bryant
/s/ DEBORAH A. COLEMAN* Director February 28, 2003
Deborah A. Coleman
/s/ A. RICHARD NEWTON* Director February 28, 2003
A. Richard Newton
/s/ SASSON SOMEKH* Director February 28, 2003
Sasson Somekh
/s/ STEVEN C. WALSKE* Director February 28, 2003
Steven C. Walske
*/s/ Steven K. Shevick
By: Steven K. Shevick, Attorney-in-fact
II-9
CERTIFICATIONS
I, Aart J. de Geus, certify that:
1. I have reviewed this annual report on Form 10-K of Synopsys, Inc.;
2. Based on my knowledge, this annual report does not contain any
untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this
annual report; and
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure
that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this annual report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the filing date of
this annual report (the "Evaluation Date"); and
c) presented in this annual report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;
5. The registrant's other certifying officer and I have disclosed,
based on our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):
a) all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant's
internal controls; and
6. The registrant's other certifying officer and I have indicated in
this annual report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.
Date: February 28, 2003
/s/ Aart J. de Geus
Aart J. de Geus
Chief Executive Officer
(Principal Executive Officer)
I, Steven K. Shevick, certify that:
1. I have reviewed this annual report on Form 10-K of Synopsys, Inc.;
2. Based on my knowledge, this annual report does not contain any
untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this
annual report; and
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure
that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this annual report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the filing date of
this annual report (the "Evaluation Date"); and
c) presented in this annual report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;
5. The registrant's other certifying officer and I have disclosed,
based on our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):
a) all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant's
internal controls; and
6. The registrant's other certifying officer and I have indicated in
this annual report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.
Date: February 28, 2003
/s/ Steven K. Shevick
Steven K. Shevick
Chief Financial Officer (Principal Financial Officer)